Literature DB >> 33475680

The Role of Temozolomide in Patients With Newly Diagnosed Wild-Type IDH, Unmethylated MGMTp Glioblastoma During the COVID-19 Pandemic.

David O Kamson1, Stuart A Grossman1.   

Abstract

Entities:  

Year:  2021        PMID： 33475680     DOI： 10.1001/jamaoncol.2020.6732

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  7 in total

1.  Stereotactic radiosurgery for IDH wild type glioblastoma: an international, multicenter study.

Authors:  Adomas Bunevicius; Stylianos Pikis; Douglas Kondziolka; Dev N Patel; Kenneth Bernstein; Erik P Sulman; Cheng-Chia Lee; Huai-Che Yang; Violaine Delabar; David Mathieu; Christopher P Cifarelli; David E Arsanious; Basem A Dahshan; Joshua S Weir; Herwin Speckter; Angel Mota; Manjul Tripathi; Narendra Kumar; Ronald E Warnick; Selcuk Peker; Yavuz Samanci; Gene Barnett; Farid El Hefnawi; Ghusn Al Sideiri; Jason Sheehan
Journal:  J Neurooncol       Date:  2021-11-19       Impact factor: 4.130

Review 2.  Efficacy and safety of extended adjuvant temozolomide compared to standard adjuvant temozolomide in glioblastoma: Updated systematic review and meta-analysis.

Authors:  Tejpal Gupta; Riddhijyoti Talukdar; Sadhana Kannan; Archya Dasgupta; Abhishek Chatterjee; Vijay Patil
Journal:  Neurooncol Pract       Date:  2022-05-07

3.  Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making.

Authors:  Mary Jane Lim-Fat; Gilbert C Youssef; Mehdi Touat; J Bryan Iorgulescu; Sydney Whorral; Marie Allen; Rifaquat Rahman; Ugonma Chukwueke; J Ricardo McFaline-Figueroa; Lakshmi Nayak; Eudocia Q Lee; Tracy T Batchelor; Omar Arnaout; Pier Paolo Peruzzi; E Antonio Chiocca; David A Reardon; David Meredith; Sandro Santagata; Rameen Beroukhim; Wenya Linda Bi; Keith L Ligon; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2022-07-01       Impact factor: 13.029

Review 4.  Updates in IDH-Wildtype Glioblastoma.

Authors:  Mary Jane Lim-Fat; James R Perry; Jawad M Melhem; Jay Detsky
Journal:  Neurotherapeutics       Date:  2022-05-31       Impact factor: 6.088

5.  A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study.

Authors:  Hao-Wen Sim; Kerrie L McDonald; Zarnie Lwin; Elizabeth H Barnes; Mark Rosenthal; Matthew C Foote; Eng-Siew Koh; Michael Back; Helen Wheeler; Erik P Sulman; Michael E Buckland; Lauren Fisher; Robyn Leonard; Merryn Hall; David M Ashley; Sonia Yip; John Simes; Mustafa Khasraw
Journal:  Neuro Oncol       Date:  2021-10-01       Impact factor: 13.029

6.  Newly diagnosed Glioblastoma Multiforme (GBM) during COVID-19 pandemic: changes in therapeutic approach to minimize in-hospital SARS-COV-2 contagion in pre-vaccine era.

Authors:  Valeria Internò; Roberta Rudà; Maria Chiara Sergi; Riccardo Soffietti; Camillo Porta
Journal:  Acta Biomed       Date:  2022-07-01

7.  METTL3 Promotes the Resistance of Glioma to Temozolomide via Increasing MGMT and ANPG in a m6A Dependent Manner.

Authors:  Jia Shi; Gang Chen; Xuchen Dong; Haoran Li; Suwen Li; Shan Cheng; Yongdong Li; Liping Wang; Jiaqi Yuan; Zhiyuan Qian; Jun Dong
Journal:  Front Oncol       Date:  2021-07-15       Impact factor: 6.244
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.